The British Business Bank has made its biggest commitment to date after pledging £100 million to Apposite Healthcare Growth I. The fund, from specialist healthcare and life sciences investor Apposite Capital, will support the growth of health technology companies, with a particular focus on the UK.
As well as being the British Business Bank’s largest fund commitment to date, the announcement also represents its first commitment to Apposite Capital. The fund will invest in innovative companies across medical products, life sciences tools, digital health, diagnostics and pharmaceutical outsourcing services.
The aim of the fund is to address the shortage of scale-up capital available to UK life sciences companies approaching key stages of growth. As such, it is aligned with the bank’s broader strategy of building deeper pools of scale-up funding.
Investments made through the fund will help UK companies develop the technologies and services required to improve patient outcomes and bolster access to innovative healthcare. In addition, it will also enable scale-up businesses to create highly skilled jobs, while competing on the global stage.
Mark Andrews, investment director, funds, life sciences at British Business Bank, commented: “The need for scale-up funding is especially pronounced in life sciences.”
“However, there remains a shortage of later-stage funds, meaning that many promising life sciences companies cannot fulfil their potential in the UK and may embark on premature or sub-optimal exits. Apposite’s new fund has a clear focus on growth stage investing in life sciences and will help convert world-leading UK science into global companies.”